EMA: AstraZeneca COVID-19 vaccine is indeed related to thrombosis

EMA: AstraZeneca COVID-19 vaccine is indeed related to thrombosis.  European Medicines Agency (EMA) has repeatedly said that AstraZeneca vaccine “does not increase the risk” and cannot confirm the connection with thrombosis.

On Tuesday (6th) local time, Marco Cavaleri, chairman of the European Medicines Agency’s (EMA) vaccine evaluation team, said that therewas indeed a connection between AstraZeneca’s COVID-19 vaccine and a very rare blood clot in the brain, but the possible cause is still not clear.

The senior official pointed out in an interview that compared with the general population, the number of cases of cerebral thrombosis among young people who have been vaccinated with AstraZeneca is significantly higher than expected, and the proportion of young female patients is particularly prominent. .

“In my opinion, we can now say that it is clear that (thrombosis) is related to the vaccine. However, we still don’t know what causes this reaction. These cases of thrombosis and thrombocytopenia are the main things that need to be studied in depth. Problem.” he added.

EMA subsequently said in a statement that the review of the vaccine is ongoing and the results are expected to be announced on Wednesday or Thursday. According to Cavaleri, EMA will point out a connection between the two in its review report, but it is unlikely that this week will give instructions on the age of the vaccine recipients. An AstraZeneca spokesperson declined to comment on the matter.

It is worth noting that this latest statement is completely different from the previous statement of EMA. Previously, the agency had repeatedly served as AstraZeneca’s vaccine platform, saying that its vaccine “does not increase the risk” and could not confirm the connection with thrombosis. Last month, EMA also issued a statement twice, stating that the vaccine “has not increased the overall risk of thrombotic events” and “no specific risk factors have been found”, and vaccination “has more advantages than disadvantages”.

In fact, since European countries began to vaccinate AstraZeneca widely, many countries have reported cases of blood clots and even death in the vaccinators. Data as of the end of March showed that 62 of the 9.2 million AstraZeneca vaccinators in the European Economic Area had symptoms of thrombosis.

This has made European countries “panic”, and some countries including France, Germany and the Netherlands have suspended the use of the vaccine for young people. In addition, according to the latest news, Oxford University has also suspended trials of AstraZeneca’s COVID-19 vaccine in children and adolescents.

Scientists have also been exploring the possible reasons why extremely rare blood clots occur within a few days or weeks after vaccination with AstraZeneca. European researchers have proposed a theory that vaccines trigger an unusual antibody in some rare cases; others are trying to understand whether these cases are related to contraceptives.

Armando Genazzani, a member of the EMA Committee for Human Medicines (CHMP), said in an interview that the blood clot is “credible” with the AstraZeneca vaccine.

According to him, the vaccine is based on an improved chimpanzee adenovirus vector ChAdOx1 developed by the University of Oxford. It is one of several adenovirus vector new coronavirus vaccines, and it is also the first time that a virus vector vaccine has been promoted globally.

(source:internet, reference only)

Disclaimer of medicaltrend.org